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ABSTRACT 
Multi-drug resistance (MDR) continues to be a major impediment in the successful treatment of 
cancer. The two efflux transporters, P-glycoprotein (P-gp) and the MDR-Associated Protein 
(MRP1) are major contributors to cancer MDR clinically. The upregulation of P-gp leading to 
MDR was initially understood to occur via pre- and post-transcriptional mechanisms only. 
However, we demonstrated that microparticles (MPs) mediate the intercellular exchange and 
trafficking of bioactive material including functional P-gp and selected modulatory miRNAs. This 
exchange of P-gp leads to the dissemination of MDR within a cancer cell population. These 
findings have significant implications in understanding the cellular basis governing the 
intercellular acquisition of deleterious traits in cancers, serving to substantially advance our 
understanding of the molecular basis for the emergence of MDR in cancer clinically.  
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The clinical problem of drug resistance in the treatment of cancer 
Although targeted therapies provide a rational and selective modality in cancer therapeutics, 
the development of drug resistance and the subsequent result of tumour unresponsiveness 
continue to plague clinical oncology. Drug resistance is seen when tumours that have been 
responding favourably to chemotherapeutic treatment suddenly reoccur or when the tumour 
fails to respond to initial treatment [1]. Numerous mechanisms contributing to drug resistance 
have been reported. These include reduced drug uptake, mutated and/or altered expression of 
drug targets, enzymatic inactivation of drugs, drug efflux mechanisms and alterations in 
apoptosis, senescence and repair mechanisms. In addition to resistance to a single drug, cancer 
cells often display a cross resistance to a diverse range of unrelated drugs resulting in a 
phenomenon known as multidrug resistance (MDR).  
 
Multi-drug resistance in cancer 
Multi-drug resistance (MDR) is typically characterized by a cross resistance to a wide range of 
pharmacologically unrelated drugs following the exposure of the cancer to a single anticancer 
agent [2]. MDR is mainly attributed to a reduced intracellular drug accumulation in cancer cells 
by virtue of increased drug efflux from within the cancer cell [3]. Consequently, sub-lethal 
intracellular drug concentrations are maintained, and the cell survives cytotoxic drug exposure. 
Classical MDR is frequently attributed to the elevated expression of members of the ATP Binding 
Cassette (ABC) superfamily of membrane transporters. P-glycoprotein (ABCB1/MDR1/P-gp) and 
the MDR Associated Protein 1 (ABCC1/MRP1) comprise two of the most widely studied 
molecules that underpin mechanisms of active efflux implicated in cancer MDR.  
 
P-gp and MRP1 and their role in conferring MDR 
P-glycoprotein (P-gp/MDR1/ABCB1):P-gp is a 170 kDa phosphoglycoprotein, encoded by the 
human ABCB1 gene, located on the long arm of chromosome 7, which utilizes energy released 
from ATP hydrolysis for drug efflux across cell membranes [4]. P-gp is a promiscuous drug 
transporter with a physiological role in binding and effluxing a wide array of structurally and 
functionally unrelated compounds thereby protecting both cells and the organism as a whole 
from xenobiotics. This remarkable efflux capacity reduces the intracellular concentration of a 
wide range of chemotherapeutics, leading to MDR and anticancer treatment failure. Most, but 
not all P-gp substrates are hydrophobic organic compounds of large molecular weight (> 400), 
that are amphipathic, possess a planar ring system and carry a positive charge at physiological 
pH [5]. P-gp substrates therefore span various therapeutic drug classes including; typical 
anticancer agents (anthracyclines, vinca alkoloids, taxanes), HIV protease inhibitors, 
antipsychotics, natural products (colchicine and curcuminoids), linear and cyclic peptides, 
steroids, fluorescent dyes, γ-emitting radiopharmaceuticals and many other miscellaneous 
agents [2, 6].  
 
The expression of MDR1 or ABCB1 gene is often related to poor remission and survival rates 
across many malignancies, serving as a predictive indicator of anticancer treatment failure. P-gp 
overexpression is observed across many human cancers including hematopoietic cancers such as 
acute myeloid leukaemia [7, 8] and acute lymphoblastic leukaemia [9]; childhood cancers such 
as soft tissue sarcoma [10], neuroblastoma [11] and fibrosarcoma [12]; gastrointestinal tract and 
genitourinary system malignancies [12], osteosarcoma [13], breast cancer [14], non-small cell 
lung carcinoma [15] and prostate cancer [16]. P-gp related MDR may be classified as "intrinsic" 
in tumours of the colon, renal cell carcinomas, hepatocellular carcinomas, pancreatic 
carcinomas and pheochromocytoma, which innately express high P-gp [17-19]. These tumours 
usually fail to respond to primary treatment, by virtue of their intrinsic resistance to therapy. On 
the other hand, in many other malignancies, P-gp overexpression is induced during therapy 
whereby initially responding tumour returns refractory to many agents contributing to 
"acquired" MDR [2]. Such malignancies include that of the breast and the ovary [20, 21]. 
 
MDR associated protein 1 (MRP1/ABCC1):MRP1, encoded by the human ABCC1 gene (located 
on chromosome 16) [22], similarly has an extraordinary capacity to transport a wide range of 
substrates.  Although a significant overlap exists with the substrate specificity of P-gp, MRP1 
also transports diverse physiological substrates including; glutathione [23], glucuronide and 
sulphate conjugates, organic anions and heavy metals [24, 25]. Many of its substrates are 
xenobiotics used as antineoplastic agents including the folate-based antimetabolites, 
anthracyclines and anti-androgens [25]. The clinical relevance of MRP1 overexpression has been 
associated with several human malignancies such as a wide range of haematological and solid 
tumours [26]. Its overexpression is implicated in MDR, being correlated with poor prognosis and 
survival in non-small cell lung carcinoma [27], breast cancer [28], prostate cancer [16] and 
childhood neuroblastoma [29].   
 
a. P-gp and MRP1 structural homology. P-gp (170 kDa) and MRP1 (190 kDa) are single 
polypeptides, topologically composed of a minimum of four core functional elements; namely 
two transmembrane domains (TMD1 andTMD2) forming the pathway for transport of substrates 
and two nucleotide binding domains (NBD1 and NBD2) that hydrolyse ATP for the efflux function 
[30]. Each TMD in P-gp typically consists of six putative α-helices. The topology of MRP1 is 
similar to that of P-gp, but it possesses an additional N-terminal domain with five putative α-
helical TMD (TMD0) of unknown function [2, 31].  
 
b. Transporter functional redundancy. The human genome encodes for 49 ABC transporters of 
which, those with multidrug resistance capabilities are ubiquitously expressed at physiological 
barriers in the body. Specifically, P-gp is highly expressed on the apical membranes of the 
intestine, colon, pancreas and renal proximal tubule, hepatocytes and in the endothelial cells 
lining capillaries in the brain, testis, placenta and inner ear [6]. Likewise, although MRP1 is 
ubiquitously expressed in the body, highest expression levels are found in the lung, testis, 
kidney, heart and placenta [27]. Consistent with their localisation at pharmacological barriers, 
these transporters serve an essential role in protecting both vital organs and the organism as a 
whole from xenobiotic exposure. A functional redundancy exists among these transporters, 
which may be attributed to their significant tissue colocalisation, broad and overlapping 
substrate specificities and a significant sequence homology. This redundancy ensures a fail-proof 
survival mechanism for preserving the organism from xenobiotic insult. Similar to P-gp, MRP1 
has been reported to be transferred via MPs and is functional in a time dependent manner in 
drug sensitive leukaemia cells. Following their MP-mediated transfer, a kinetic difference 
between P-gp and MRP1 becoming functional in the recipient cells has been reported [32]. 
Another transporter ABCG2 plays a role in MDR, however nothing has been reported on their 
role in MP-mediated transfer. This is currently under investigation in our lab. 
  
Almost half the members (namely ABCA1-12, ABCB1-11, ABCC1-12, ABCG)  of this family have a 
role in conferring drug resistance in vitro and clinically [31] and have various immune system 
roles [34, 35] evading tumour immune responses [36], making them ideal therapeutic targets. 
However, the existing functional redundancy has complicated attempts for the pharmacological 
circumvention of P-gp mediated MDR. Current drug discovery screening programs include the 
development of MDR reversal agents that can simultaneously inhibit multiple transporters 
rather than single entities [6]. However, this approach is clinically limited, due to the poor 
specificity, low affinity for the binding site and interference with the physiological role of these 
transporters expressed at pharmacological barriers [37], resulting in severe side effects.  
 
c. Cytoskeletal anchorage of P-gp to the cell membrane. Interactions between the plasma 
membrane and the cytoskeleton are essential in cell adhesion, cell signalling, membrane 
trafficking, cell motility, apoptosis and MP formation [38-40]. The FERM domain (F for 4.1 
protein, ezrin, radixin and moesin) proteins play an important role in these processes and 
possess a unique module required to interface membrane proteins with the cytoskeleton. These 
specialized groups of macromolecules are found in higher order structures including sites of cell-
cell and cell-to-extracellular matrix attachment [41]. Furthermore, FERM domain proteins have 
been shown to be responsible for the direct association between MDR proteins and the 
cytoskeleton. Specifically, P-gp colocalises with ezrin in IFN-γ treated monocyte derived 
macrophages [42] and with ezrin, radixin and moesin (ERM) proteins on pseudopods/ uropods 
in resistant lymphoid cells [38]. In addition, there could be a potential indirect involvement of 
lipid micro-domains such as caveolae in the cytoskeletal anchorage of P-gp to the cell 
membrane. Indeed, P-gp and MRP1 have been shown to be localised in caveolae and the 
expression of Caveolin-1 may directly modulate the functional activity of P-gp [43-44]. 
Disruption of the ERM–P-gp association impairs P-gp function and results in a cellular 
redistribution of P-gp [38], supporting an essential role for the ERM proteins in the plasma 
membrane localisation of P-gp. Consistent with this, the actin-P-gp interaction is also required 
for the endosomal trafficking of P-gp to the plasma membrane [38, 45]. These studies establish 
that the membrane localisation of P-gp occurs by direct actin anchorage through the FERM 
domain proteins [46]. We recently showed that ezrin was present in both the parental 
leukaemia and breast cancer cells and their P-gp over expressing MDR variants. In addition, the 
levels of ezrin was also found to be dependent on the MDR protein levels [47]. 
 
Another cell adhesion molecule that interacts with P-gp via FERM domain binding proteins is 
CD44. CD44 is the major surface receptor to hyaluronan, which is involved in cell adhesion, 
metastasis and motility [48]. CD44 assembles intracellular complexes involving the FERM 
domain proteins, the binding of which, anchors CD44 to actin and influences downstream 
signalling. CD44 and P-gp interact in carcinoma cell lines to promote cell migration and invasion 
[49]. Both CD44 and P-gp can be co-immunoprecipitated, are colocalised and their expression 
coregulated, supporting a molecular interaction between the two proteins [49, 50]. P-gp 
complexes with activated CD44 via ERM intermediate with membrane co-localisation dependent 
on CD44 interaction [51]. 
 
Non-genetic modulation of MDR acquisition 
Modulation of MDR expression was understood to exclusively occur endogenously via pre- or 
post-transcriptional mechanisms. Increased mRNA as a result of gene amplification, enhanced 
gene transcription and increased mRNA half-life [52, 53], gene amplification and increased 
mRNA stability due to prolonged exposure to several cytotoxic drugs [54] have been shown to 
result in MDR overexpression in cancer cells. In addition, modulation in protein stability, plasma 
membrane incorporation [55] and increased P-gp trafficking [21] have been reported for P-gp 
upregulation at the protein level. Although the genetic basis for MDR acquisition is well 
characterized, little was known about the role of non-genetic mechanisms in the overall 
acquisition of this phenotype (Figure 1A). The non-genetic acquisition of membrane proteins via 
cell-cell communication modalities provides an efficient and alternative pathway for the cellular 
acquisition and dissemination of traits. Various supramolecular mechanisms involving direct cell-
cell contact [56], cellular membrane blebs like microparticles (MPs) [57], exchange of membrane 
fragments or trogocytosis [58], tunnelling nanotubes  [59, 60] and cytoneme or filopodial 
bridges [61] have been observed to form the basis of cellular communication leading to 
intercellular membrane protein transfer. Some of these mechanisms are depicted in Figure 1B. 
 
Microparticles play a unique role in intercellular communication 
Among the most intriguing mechanisms of intercellular exchange is the generation and 
intercellular trafficking of MPs. MPs serve as natural physiological vehicles, via which cell surface 
and intracellular molecules exit the donor cell, are carried to another cell (long and short range) 
in the intact state and exert their effect on recipient cell populations. Levchenko and coworkers 
demonstrated the intercellular transfer and ‘non-genetic’ acquisition of P-gp in MDR [56]. The 
intercellular transfer of functional P-gp from P-gp (+) donor cells to P-gp (-) recipient cells was 
demonstrated following co-culture of parental cells with their MDR derivative cells. On the basis 
of filtered medium experiments, the authors concluded that protein transfer was mediated by 
direct cell to cell contact. The non genetically acquired phenotype was unstable and required a 
constant exposure to either a selecting pressure (an anticancer drug) or the presence of MDR 
cells so as to maintain the acquired phenotype [56]. Mack and co-workers, in 2000 
demonstrated the role of MPs in transferring CCR5, a 62 kDa chemokine receptor. They showed 
that CCR5, the principal co-receptor which enables the transmission and propagation of 
macrophage-tropic human immunodeficiency virus (HIV-1), were transferred by microparticels 
from the surface of CCR5 (+) cell to recipient CCR5 (-) cells, conferring susceptibility to HIV-1 
infection [62]. In 2009, we demonstrated that MPs serve as intercellular vectors of MDR 
dissemination, and acquisition via intercellular transfer of functional P-gp [63]. Since our initial 
finding we have shown MPs to play an even more alarming role in cancer biology by; (i) 
incorporating and transferring a variety of MDR proteins (both P-gp and MRP1) and nucleic acids 
[32, 64, 65], (ii) re-templating the transcriptional landscape of recipient cells to ensure the 
acquisition of deleterious cancer traits [32, 65], (iii) displaying MDR proteins in inside out 
orientation in MP exposed recipient cells, with respect to untreated cells across different 
malignancies (Gong et al., 2013, EJP, in press) and (iv) by sequestering anticancer drugs within 
their intravesicular space, thereby reducing the amount of free drug available to cancer cells 
(Gong et al., 2013, EJP, in press). This serves as a parallel pathway in the acquisition of MDR in 
malignancies.  
a. Microparticles in physiology and pathology. MPs are small membrane vesicles (0.1-1 µm in 
diameter) derived from the ubiquitous cellular phenomenon of plasma membrane budding [66]. 
MPs display phosphatidylserine (PS) on their surface and are distinguished from exosomes by 
size (exosomes typically ranging 40-100 nm in diameter), phenotype and origin (exosomes 
originate from endocytic bodies) [67]. MPs are released, under normal physiological conditions, 
from the plasma membranes of various cell types including; platelets, macrophages, monocytes, 
T-cells, endothelial cells and erythrocytes [68-70]. However, in response to cell stimulation or 
stress, the vesiculation undergoes a dramatic acceleration and qualitative change [71].  
MPs were initially considered as inert side products of cellular activation. They have now been 
reported as important intermediaries in inflammation, coagulation and vascular homeostasis 
[72]. Many pathological conditions and diseased states such as autoimmune disorders, 
atherosclerosis, HIV infections, cerebral malaria, sepsis [73-76] and cancer [63, 64] have been 
reported to have elevated levels of systemic MPs. In addition, MPs shed from cancer cells are 
associated with tumour cell invasiveness [77], evasion of immune surveillance [78], angiogenesis 
[79], chemoresistance [63, 65] and contribute to the hypercoagulable state observed in many 
malignancies [80,81], thereby acting as important mediators in paraneoplastic syndromes 
(Figure 2).  
 
 b. Microparticle biogenesis. MPs are released upon cellular activation or during apoptosis 
following a breakdown of the plasma membrane's natural phospholipid asymmetry and a 
remodelling of the cytoskeleton [2, 66]. At steady state, the cell membrane displays an 
asymmetric phospholipid configuration. Upon cell activation, an increase in intracellular calcium 
modulates the enzymatic regulators governing phospholipid asymmetry, resulting in a 
scrambling of lipids between the two membrane leaflets. The increase in cytosolic calcium 
activates the enzyme, calpain which serves to hydrolyse the actin binding proteins and disrupt 
the cytoskeletal scaffold immediately under the membrane bilayer. The structural loss facilitates 
membrane budding and MP shedding from the cell [82]. 
 
c. Microparticle cargo. Upon release, MPs carry cellular proteins, second messengers, growth 
factors and genetic material from their cells of origin [2, 83] and comprise the major source of 
RNA (ribosomal RNA (rRNA), messenger RNA, (mRNA) and microRNA (miRNA) in systemic 
circulation [2, 64, 84-86]. MPs also carry the transcripts of enzymes responsible for its 
biogenesis (floppase and scramblase) together with the transcripts of enzymes required for 
miRNA biogenesis (Dicer, Drosha and Argonaute) [64]. The intravesicular localisation of nucleic 
acid cargo in the MPs prevents their systemic degradation by blood nucleases, thereby 
constituting MPs as major source of RNA in systemic circulation [86]. Given that MPs are 
emerging as an important source of miRNA in the circulation of cancer patients [87, 88] it is 
conceivable to propose a role for MP in the aberrant miRNA levels displayed in oncogenesis and, 
potentially, in metastasis. Indeed the detection of circulating tumour-derived transcripts from 
melanoma, breast and lung cancer patients have defined MPs as markers of diagnostic and 
prognostic significance [64, 87].  
 
In addition, MPs represent a concentrated source of bioactive molecules and have been shown 
to relay significant detrimental effects following their transfer onto target cells in vitro. A 
process of selective packaging or sorting of cargo is operational in the MPs, whereby MPs 
harbour differential amounts of the bioactive material with respect to their donor cells [64, 65]. 
Upon transfer, we have shown MPs can impose the dominant donor cell trait onto recipient cells, 
thereby effectively re-templating the transcriptional landscape of recipient cells to ensure the 
acquisition of deleterious cancer traits [64, 65]. 
 
We recently showed that MPs cargo also includes cytoskeletal anchorage proteins such as ezrin 
and CD44, which are associated with membrane localisation of P-gp. Briefly, we demonstrated 
that the ezrin was present in both the parental and their P-gp over expressing MDR variants of 
leukaemia and breast cancer cells. MPs derived from the drug resistant cells selectively 
packaged higher levels of ezrin, with respect to their donor cells. Upon co-culture of these drug 
resistant MPs with parental recipient cells, we did not observe any significant increase in ezrin 
over and above the endogenous levels already present in the recipient cells [47].In addition to 
ezrin, we have shown that breast cancer-derived MPs selectively package CD44 (isoform 10) 
with respect to its comparator the leukaemia-derived MPs [47]. Furthermore, we demonstrated 
that the breast-cancer derived MPs display tissue selectivity in transferring P-gp to malignant 
cells only in comparison to the leukaemia derived MPs, which effectively cross-talk across both 
malignant and non-malignant cells [47]. We proposed that the differential presence of CD44 
(isoform 10) on the breast cancer derived MPs may contribute to the observed P-gp transfer 
selectivity [47].   
 
microRNA cargo. miRNAs are highly conserved, single-stranded non-coding regulatory RNA, 
typically  19–25 nucleotides in length. These nucleic acids modulate the activity of specific 
mRNA targets by pairing with partial complementary sites in the 3’- untranslated region (UTR) of 
target genes [2]. miRNA synthesis begins in the nucleus by RNA polymerase II to form primary 
miRNA (pri-miRNA). Pri-miRNA is processed by the ribonucleases, Drosha and Dicer to generate 
mature miRNA. The single stranded miRNA, in association with Argonaute 2, binds to 
complementary sequences in the 3' untranslated region (UTR) of target transcripts to regulate 
gene expression either by translational repression, activation or degradation of the mRNA 
transcript [2]. 
At present over 1000 human miRNAs have been identified targeting an estimated 30% of human 
genes [89], serving as important regulators of a wide range of pathophysiological processes [90]. 
By targeting several genes, miRNAs play important roles in complex pathophysiological 
networks including cell proliferation, differentiation, apoptotic cell death, stress resistance, 
physiological metabolism and resistance to chemotherapeutic agents [91-94]. Consequently, 
aberrant expression of miRNAs has been associated with malignancy, including; cancer stage, 
disease progression and metastatic spread [64, 95, 96]. Specifically, we have demonstrated that 
certain miRNAs are selectively packaged in MPs derived from both haematological and non-
haematological cancer cells. These miRNAs are involved in pathways implicated in cancer 
pathogenesis, membrane vesiculation and cascades regulated by ABC transporters [64]. MPs 
incorporate miRNAs and act as vectors, facilitating their intercellular functionality between cells 
[64, 97, 98]. We also showed that following MP co-culture with recipient parental cells, miRNA 
expression trends of the MP acquired recipient cells were reflective of that of the MP donor 
cells. Thereby, demonstrating that the recipient cells reflect the donor trait following MP-
mediated transfer of cargo [64].  
miRNA and MDR. miRNAs play an important role in the regulation of chemoresistance. 
Resistance to topetecan, doxorubicin, methotrexate, docetaxel and cisplatin have been 
correlated with alterations in miRNA expression in tumour cells [99-104]. However, very little 
was known about the role of miRNAs in ABC transporter expression and function. miR-27a and 
miR-451 expression were shown to activate MDR1/P-gp expression in resistant human ovarian 
cancer [65, 105]. We demonstrated the involvement of miR-27a together with the modest 
amount of transcript delivered by MPs to contribute to a modest increase in ABCB1 levels in 
breast cancer cells [65]. Consistent with earlier observations in breast cancer tissues [106], we 
identified an inverse relationship between MRP1 mRNA and miR-326 levels in leukaemia cells 
[65]. Likewise, the overexpression of miR-21 and the downregulation of the tumour suppressor 
protein PDCD4 in breast cancer has been shown to upregulate P-gp expression leading to 
chemoresistance [107]. miR-345 and miR-7 have been shown to target MRP1, with the former 
displaying lower expression in MDR breast cancer cells relative to parental cells [103]. Recently, 
miR-297 was shown to play a role in the development of MDR by the modulation of MRP2 in 
colorectal cancer cells [108]. These emerging data substantiate a role for miRNAs, including that 
conferred onto recipient cells by MPs in contributing to the emergence of MDR and regulation 
of transporter expression in cancer cells. 
 
Role of microparticles in conferring P-gp mediated MDR in Cancer 
MPs carry surface antigens, cytoplasmic and nuclear constituents from their originating cell [62, 
64, 109] and mediate intercellular cross-talk by transferring receptors, antigens and cytokines 
from donor cells to recipient cells [66]. The presence of cell adhesion molecules on MP supports  
a capacity for target cell binding and intercellular crosstalk [62]. We first described a novel “non-
genetic” mechanism for the acquisition of MDR, whereby MPs serve as vectors in the 
intercellular transfer of functional P-gp from MDR donor cells to drug sensitive recipient cells 
(Figure 1A) [63]. To our knowledge, this was the first report that a protein as large as P-gp, a 170 
kDa polypeptide, consisting of 1280 amino acids that spans the plasma membrane 12 times 
[110], could be transferred by submicron membrane vesicles, into recipient cells whilst retaining 
its functional state. Furthermore this intercellular pathway occurs across haematological and 
non-haematological malignancies [65] with P-gp transfer occurring as early as 2 hours and 
functional MDR acquired within 4 hours of transfer [63]. However, it still remains to be 
elucidated as to how MPs are incorporated within the recipient target cells enabling the 
effective transfer of functional P-gp and other antigens across cells. Although the exact 
mechanism is still unclear, previous studies have shown that on interaction with recipient 
human brain endothelial cells, platelet derived MPs are internalised within vesicular structures 
and their different components are either degraded or recycled/endocytosed inside the target 
cell [111]. This is currently under study and we suggest that processes such as MP membrane 
fusion, endocytosis, phagocytosis may be involved. 
 
Since these initial findings we have demonstrated using direct immunolabelling and flow 
cytometric analysis, that the extent of MP-mediated transfer of P-gp is dependent on MP 
amount (Figure 3). This data shows that as little as 30 μg of total MP protein is able to 
transfer functional P-gp (10% total P-gp with respect to parental cells) to recipient drug 
sensitive cells. In addition, 180 μg of total MP protein is observed to be optimal for 
maximal P-gp transfer and function (lowest intercellular drug accumulation) (Figure 3). 
Several reports have demonstrated that elevated numbers of platelet-derived MPs are 
present in metastatic gastric [112], breast [113, 114] and pancreatic cancer [113]. In 
addition, a recent study showed that plasma samples of breast cancer patients had 
10,000 x10
6
/L number of total MPs higher than the control samples [115]. Extrapolating 
this MP number to our study, as little as 3x10
5
 number of MPs (30 μg) as used in in vitro 
is clinically relevant under physiological conditions. We further validated the transfer of 
functional P-gp following whole cell drug exclusion assays using two distinct fluorescent P-gp 
drug substrates, daunorubicin (DNR) and rhodamine 123 (Rh123) (Figure 4). These studies 
confirm that MP-mediated transfer of P-gp results in the dissemination of the MDR phenotype 
whereby cells exhibit cross-resistance to unrelated substrates such as DNR and Rh123, in vitro, 
consistent with our previous reports [63].  
 
Stability of the acquired trait 
We have shown that MPs mediate the transfer of MDR proteins from donor cells to drug 
sensitive cells, thereby conferring the MDR phenotype onto the recipient cell. In addition, we 
demonstrate that the acquired MDR trait in the recipient cell is stable for at least 5 days in vitro, 
in the absence of any selecting pressure such as cytotoxic drugs or subsequent exposure of MPs 
themselves (Figure 5). 
 
Our in vivo studies conducted using a murine MCF-7 tumour xenograft model show that MP-
mediated P-gp is rapidly acquired by drug sensitive tumours within 24 hours of MP exposure 
with P-gp localising deep within the tumour core. This acquired phenotype is stable for at least 2 
weeks in the absence of further MP exposure or a selective pressure (drugs or resistant cells) 
[47]. The stability and the occurrence of this pathway in vivo further emphasize the severity and 
the deleterious effect of MPs in conferring MDR and other deleterious traits in cancer, with 
potential clinical significance.  
 
Implications for alternative treatment strategies and future perspective 
Over the past decade MP biology has emerged quickly and has been attracting growing interest 
in the context of disease pathophysiology. MPs are mostly identified as important natural 
vehicles in which intracellular macromolecules are packaged and exported to another cell, either 
locally or distant from their site of origin, in the intact state. Although very little is currently 
known about the clearance of MPs, it has been suggested that the interactions of MPs with 
other cells may represent a mechanism for their elimination from the circulation [73]. Indeed, 
there has been a recent report on the clearance of transfused platelet derived MPs (PMP) in 
human blood, with a half-life-time of ~6 hours [116].  
 
MDR is major obstacle to effective chemotherapy. In addition to this, the coexistence of a ‘non-
genetic’ mechanism of dissemination complicates the situation further. At present, the area of 
MP-mediated transfer of MDR is an emerging field with no clinical study available to date. 
Studies done till date have generally used highly drug resistant cell lines expressing very high 
levels of P-gp. Clinical implications of MP-mediated MDR will be supported by further future 
research in patient tumour samples expressing physiologically low levels of P-gp. However, our 
studies in both leukaemia and breast cancer have shown MPs to be important mediators in the 
intercellular transfer of MDR and other deleterious cancer traits in vitro and in vivo. The 
elucidation and further exploration of this novel pathway could provide a mechanistic 
understanding of the intercellular acquisition of deleterious traits in cancer clinically. The 
demonstration of the role of MPs in the transfer of P-gp and acquisition of MDR has important 
implications for developing therapeutic strategies to prevent the spread of MDR clinically. Thus 
it is inferred that in addition to the current MDR treatment strategies that incorporate 
conventional P-gp inhibitors, once clinically proven, it would be worthwhile to consider 
inhibition of the MP-mediated component of this pathway [117]. MP production has been linked 
to cancer progression and metastasis; hence inhibiting MP formation (by several known MP 
inhibitors such as calpain inhibitors, calcium channel blockers, ROCK inhibitors and pantethiene) 
[117] may have the potential to not only hinder cancer cell proliferation but also their ability to 
transfer MDR. In addition, MPs from biological fluids could provide a non-invasive diagnostic 
predictive biomarker, through their nucleic acid and protein signatures in certain disease states. 
Dissecting the nature and implications of this pathway represents a new exciting challenge in 
cancer biology and clinically in cancer therapeutics. 
 
EXECUTIVE SUMMARY  
The clinical problem of drug resistance in the treatment of cancer 
• Tumour unresponsiveness to chemotherapy is a major concern in cancer treatment. 
• Drug resistance is a multimodal phenomenon. 
•  Multi-drug resistance (MDR) is more serious still where cancer cells display cross-
resistance to diverse drugs. 
Multi-drug Resistance in cancer  
• MDR is characterised by reduced intracellular drug accumulation attributed to the 
overexpression of two drug transporters, P-gp and MRP1 in cancer cells. 
• A functional redundancy exists among these transporters, ensuring a fail-proof survival 
mechanism for the organism, but complicating pharmacological circumvention of P-gp 
mediated MDR.  
• FERM domain proteins and CD44 associate with P-gp leading to the interaction with the 
plasma membrane and cytoskeleton, essential in cell adhesion, metastasis and motility. 
• MPs derived from the drug resistant cells selectively package higher levels of ezrin, with 
respect to their donor cells. 
• CD44 (isoform 10) is present on the breast cancer derived MPs but not leukaemia 
derived MPs, which may play a role in P-gp transfer selectivity displayed by these MPs. 
Non-genetic modulation of MDR acquisition 
• Several cell-cell communication modalities (direct cell-cell contact, microvesicles and 
microparticles, trogocytosis, tunnelling nanotubes and cytoneme or filopodial 
bridges)provide an alternative non-genetic pathway for the cellular acquisition and 
dissemination of MDR traits. 
Microparticlesplay a unique role in intercellular communication 
• MPs are important clinical mediators of various pathophysiological processes including 
inflammation, coagulation, vascular homeostasis, HIV-1 and cancer. 
• MPs serve as intercellular vectors of MDR dissemination, and acquisition via intercellular 
transfer of functional P-gp. 
• MP cargo includes cellular proteins, second messengers, growth factors, genetic 
material  (DNA, RNA, miRNA), transcripts of enzymes responsible for MP biogenesis and 
miRNA biogenesis, ezrin and CD44 from their cells of origin. 
Role of microparticles in conferring P-gp mediated MDR in Cancer 
• MP mediated transfer of P-gp occur as early as 2 hours and functional resistance 
acquired within 4 hours. 
• MP-mediated transfer of P-gp is dependent on MP amount. 
Stability of the acquired trait 
• The acquired MDR trait in the recipient cell is stable for at least 5 days in vitro, in the 
absence of any selecting pressure or subsequent exposure to MPs themselves. 
• In in vivo studies, MP-mediated P-gp is rapidly acquired by drug sensitive tumours within 
24 hours of MP exposure and this acquired phenotype is stable for at least 2 weeks in 
the absence of further MP exposure or a selective pressure. 
Implications for alternative treatment strategies and future perspective 
• The elucidation and further exploration of MP-mediated transfer of MDR provides a 
mechanistic understanding of the intercellular acquisition of deleterious traits in cancer 
clinically. 
• This pathway has important implications for developing novel therapeutic strategies to 
prevent the spread of MDR. 
• MPs from biological fluids could provide a non-invasive diagnostic predictive biomarker. 
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Figures 
 
Figure 1: (A) Mechanism of MP-mediated MDR. P-gp may be acquired by non-genetic 
mechanisms, including MP mediated MDR where MPs carrying P-gp from their originating cells 
are spontaneously shed from drug MDR
+
 donor cells. Shed MPs bind to drug-sensitive recipient 
cells and transfer functional P-gp to confer the MDR phenotype. (B) Scanning Electron 
Microscopy Image depicting the modes of intercellular communication: Human acute 
lymphoblastic leukaemia (CCRF-CEM) cells facilitate intercellular communication via tunnelling 
nanotubes (black arrow) and also by microparticles amongst others (red arrow).. The cells were 
imaged using the Zeiss ULTRA plusscanning electron microscope following fixation with 
osmium tetroxide and coating with platinum. Scale bar as shown in panel. 
 
 
 Figure 2: Role of cancer derived MPs in cancer biology:  Tumour–derived MPs affect various 
aspects of cancer biology, through their ability to selectively carry bioactive molecules and also 
to act as vectors for the horizontal transfer of their cargo. 
 
  
Figure 3: MP transfer of P-gp from MDR
+
 donor drug resistant cells to drug sensitive (MDR
-
) 
recipient cells. (A) Surface P-gp expression following MDR
- 
cell co-culture with MDR
+
MP. Cells 
were labeled with FITC-anti-P-gp (solid) or isotypecontrol (open) mAbs and analyzed by flow 
cytometry. Histograms depict percent P-gp positive populations, A: MDR
-
, B: MDR
+
, C: MDR
- 
+MP 
30 μg, 10% of MP exposed recipient cells expressed P-gp compared to untreated cells. D: MDR
- 
+MP 80 μg, 36% of MP exposed recipient cells expressed P-gp compared to untreated cells. E: 
MDR
- 
+MP 100 μg, 45% of MP exposed recipient cells expressed P-gp compared to untreated 
cells. F: MDR
- 
+MP 150 μg, 57% of MP exposed recipient cells expressed P-gp compared to 
untreated cells. G: MDR
- 
+MP 180 μg, 62% of MP exposed recipient cells expressed P-gp 
compared to untreated cells and H: MDR
- 
+MP 250 μg, 56% of MP exposed recipient cells 
expressed P-gp compared to untreated cells..(B) MP transfer of functional P-gp. Mean 
fluorescence intensity (MFI) of daunorubicin (DNR) accumulation in MDR
-
 cells with exposure to 
increasing amounts of MPs. The recipient cells post 4 h co-culture were treated with 1μM DNR 
for 1hr at 37
0
C and intracellular drug accumulation detected using flow cytometry. DNR 
accumulation in —: MDR
- 
(MFI-14.5),—: MDR
- 
+MP 15 μg (MFI-10.7), —:MDR
- 
+MP 40 μg (MFI-
9.31), —: MDR
- 
+MP 160 μg (MFI-4.45) and —:MDR
- 
+MP 180 μg (MFI-4.11). 180 µg MP in co-
culture results in maximal P-gp transfer (A) and function (lowest intracellular DNR accumulation) 
(B). Data are representative of a typical experiment.   
 
 
 Figure 4: MP-mediated transfer of P-gp from drug resistance to drug sensitive cancer cells 
leads to the MDR phenotype. Reduction in whole cell accumulation of two fluorescent drug 
substrates of P-gp, namely, (A) Rh123and (B) DNR, in drug sensitive cells co-cultured with 
increasing amounts of MPs from drug resistant leukaemic cells. Values are expressed as percent 
reduction relative to the recipient drug sensitive cells. Data represent the mean + SEM of at 
least 3 independent experiments *p < 0.05.  
 
 
 
Figure 5: Acquired MDR phenotype stable in vitro for at least 5 days. MFI of DNR cell 
accumulation in a representative experiment. MDR
- 
cells (negative P-gp control), MDR
+ 
cells 
(positive P-gp control) and MDR
- 
cells co-cultured with MPs (MDR
+
MP) from MDR
+ 
cells for 4 h, 
referred to as co-cultured cells (Co). MPs were removed by washing after 4hrs and cells left in 
culture for 5 days (Co 5days). The recipient cells post 4 h (Co 4h) and 5 days (Co 5days) were 
treated with 1μM DNR for 1hr at 37
0
C and intracellular drug accumulation detected using flow 
cytometry. Figure shows DNR accumulation in — MDR
-
, — Co 4h,∙∙∙∙ Co 5 days and — MDR
+
.      
 
